Insight Molecular Diagnostics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Insight Molecular Diagnostics şirketinin kazançları yıllık ortalama -16.6% oranında azalırken, Biotechs sektörünün kazançları yıllık 33.8% oranında artan oldu. Gelirler yıllık ortalama 10.1% oranında artan oldu.
Anahtar bilgiler
-16.63%
Kazanç büyüme oranı
27.84%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.04% |
| Gelir büyüme oranı | 10.06% |
| Özkaynak getirisi | n/a |
| Net Marj | -2,454.64% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Analiz Makalesi • May 15
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Anlatı Güncellemesi • May 15
IMDX: FDA Submission And Strengthened Cash Position Will Drive Bullish Repricing
Insight Molecular Diagnostics' analyst price target has moved from $8 to $12, with analysts pointing to secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key factors supporting this revision. Analyst Commentary Bullish Takeaways Bullish analysts view the move to a US$12 price target as reflecting reduced funding risk after the recent US$26M offering, which they see as supportive for execution on pending milestones.Anlatı Güncellemesi • Apr 28
IMDX: Upcoming FDA Review And Cash Cushion May Support Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recently completed $26M offering, which secures cash beyond a potential GraftAssureDx approval and an expected FDA submission in the coming weeks, as key drivers of their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the new $12 price target as reflecting improved funding visibility, with the recent $26M offering seen as supportive of ongoing operations past a potential GraftAssureDx approval.Anlatı Güncellemesi • Apr 13
IMDX: Upcoming FDA Submission And Cash Runway May Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26M capital raise and expectations around an upcoming FDA submission for GraftAssureDx as key supports for the new outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a US$12 price target as reflecting higher confidence that the recent US$26M capital raise supports the company through key regulatory milestones.Anlatı Güncellemesi • Mar 29
IMDX: Upcoming FDA Review And Capital Raise Will Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26,000,000 capital raise and the expected FDA submission for GraftAssureDx in the coming weeks as key factors supporting the revised target. Analyst Commentary Recent research updates give you a clearer picture of how the Street is reacting to Insight Molecular Diagnostics after its latest funding and upcoming regulatory milestones.Anlatı Güncellemesi • Mar 12
IMDX: Upcoming FDA Submission And Capital Raise Will Drive Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26m capital raise and expectations for an upcoming FDA submission for GraftAssureDx as key supports for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the move in the price target to $12 as reflecting higher confidence that the recent $26m capital raise supports the company through key regulatory milestones.Anlatı Güncellemesi • Feb 26
IMDX: Funding And Upcoming FDA Submission Will Shape Potential Upside
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key supports for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a $12 price target as reflecting higher conviction that the current funding and product plan can support the company through key milestones.Anlatı Güncellemesi • Feb 11
IMDX: Stable Outlook As Regulatory And Transplant Center Expansion Will Shape Upside
Analysts have adjusted their price target on Insight Molecular Diagnostics to reflect an updated fair value of $7.00 per share, a higher assumed future P/E of 121.71, and revised views on the discount rate and profit margin potential. What's in the News Year-end business update outlined commercial progress and the clinical trial status of the GraftAssureDx test kit, including preparation for an in vitro diagnostic de novo submission to the US Food & Drug Administration (FDA).Anlatı Güncellemesi • Jan 27
IMDX: Stable Outlook As Regulatory Progress And Transplant Testing Portfolio Will Shape Upside
Analysts have nudged their price target on Insight Molecular Diagnostics higher to reflect slightly refined assumptions on discount rate, profit margin and forward P/E. The updated target is now framed around a fair value of 7.0. What's in the News Year end business update outlines commercial progress for the GraftAssureDx test kit, including clinical trial status and plans for an in vitro diagnostic de novo submission to the United States Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026 (company update).Anlatı Güncellemesi • Jan 12
IMDX: Stable Outlook As Transplant Monitoring Pipeline And Regulatory Progress Will Support Upside
Narrative Update on Insight Molecular Diagnostics Analysts have slightly adjusted their price target on Insight Molecular Diagnostics, with the change reflecting updated fair value modeling around a 7.0% discount rate, approximately 41% revenue growth assumptions, a 16.24% profit margin, and a forward P/E near 120x. What's in the News Year end business update provided on commercial progress, including the GraftAssureDx test kit clinical trial and plans for an in vitro diagnostic de novo submission to the US Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026.Anlatı Güncellemesi • Dec 25
IMDX: Transplant Monitoring Expansion Will Drive Future Market Leadership
Analysts have modestly raised their price target on Insight Molecular Diagnostics to reflect incremental improvements in long term profit margin assumptions and a slightly lower discount rate, while maintaining broadly consistent growth expectations and valuation multiples. What's in the News Publication of a case study in the American Journal of Transplantation highlighted Insight Molecular Diagnostics' GraftAssure assay as essential for monitoring a high risk kidney transplant patient undergoing novel CD19 CAR T therapy without traditional immunosuppression (Key Developments).Anlatı Güncellemesi • Dec 11
IMDX: Transplant Monitoring Advances Will Drive Future Market Momentum
Narrative Update on Insight Molecular Diagnostics The analyst price target for Insight Molecular Diagnostics has been modestly revised upward by analysts, reflecting slightly higher fair value estimates supported by incremental improvements in projected discount rate, revenue growth, profit margin, and future price to earnings assumptions. What's in the News A published clinical study in the American Journal of Transplantation highlighted the GraftAssure assay as critical for long-term monitoring of a high-risk kidney transplant patient treated with novel CD19 CAR T therapy, confirming absence of rejection during cancer treatment (American Journal of Transplantation).Anlatı Güncellemesi • Nov 27
IMDX: Expanding Clinical Trial Participation Will Drive Market Momentum
Analysts have raised their price target for Insight Molecular Diagnostics from $6.13 to $7.00 per share, citing stronger expected revenue growth and improving profit margins in their updated forecasts. What's in the News Insight Molecular Diagnostics published results showing their GraftAssure assay enabled long-term non-immunosuppressed kidney transplant survival with no rejection, following CD19 CAR-T therapy in a complex patient case (study published in the American Journal of Transplantation).Seeking Alpha • Nov 14
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating
Summary Initiating coverage of Insight Molecular Diagnostics Inc. with a Hold rating due to upcoming catalysts and pending FDA submission for GraftAssureDx kidney transplant assay. IMDX's decentralized GraftAssureDx aims to disrupt the $1B+ transplant rejection testing market, offering cost-effective, localized testing versus centralized lab competitors. Key risks include clinical validation, regulatory approval uncertainty, software readiness, potential FDA delays, and a limited cash runway likely requiring further capital raises. Applying a Hold rating as IMDX advances toward FDA filing by end-2025 and eyes expansion into heart and lung transplant assays in 2026 and 2027. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 12
We Think Insight Molecular Diagnostics (NASDAQ:IMDX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, Insight...Anlatı Güncellemesi • Nov 12
IMDX: Increased Discount Rate Will Raise Uncertainty for Share Performance
Analysts have raised their price target for Insight Molecular Diagnostics from $5.42 to $6.13, citing improved revenue growth forecasts and higher profit margins as key factors contributing to the increased valuation. What's in the News Insight Molecular Diagnostics published study results in the American Journal of Transplantation, demonstrating the value of its GraftAssure assay for monitoring kidney transplant patients with severe complications.
Yeni Anlatı • Apr 13
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Insight Molecular Diagnostics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 2 | -48 | 18 | 18 |
| 31 Dec 25 | 4 | -50 | 17 | 16 |
| 30 Sep 25 | 4 | -61 | 16 | 12 |
| 30 Jun 25 | 4 | -63 | 16 | 11 |
| 31 Mar 25 | 4 | -58 | 15 | 10 |
| 31 Dec 24 | 2 | -61 | 14 | 10 |
| 30 Sep 24 | 1 | -44 | 13 | 10 |
| 30 Jun 24 | 1 | -37 | 12 | 10 |
| 31 Mar 24 | 1 | -40 | 13 | 9 |
| 31 Dec 23 | 2 | -26 | 14 | 9 |
| 30 Sep 23 | 1 | -22 | 16 | 8 |
| 30 Jun 23 | 1 | -17 | 18 | 7 |
| 31 Mar 23 | 1 | -11 | 20 | 7 |
| 31 Dec 22 | 1 | -19 | 22 | 7 |
| 30 Sep 22 | -1 | -22 | 14 | 2 |
| 30 Jun 22 | 0 | -34 | 16 | 3 |
| 31 Mar 22 | 1 | -43 | 19 | 3 |
| 31 Dec 21 | 2 | -44 | 20 | 5 |
| 30 Sep 21 | 5 | -35 | 29 | 10 |
| 30 Jun 21 | 4 | -28 | 26 | 10 |
| 31 Mar 21 | 2 | -26 | 23 | 11 |
| 31 Dec 20 | 1 | -30 | 22 | 9 |
| 30 Sep 20 | 1 | -32 | 22 | 10 |
| 30 Jun 20 | 0 | -30 | 20 | 9 |
| 31 Mar 20 | 0 | -26 | 19 | 8 |
| 31 Dec 19 | 0 | -22 | 15 | 7 |
| 30 Sep 19 | 0 | -19 | 13 | 5 |
| 30 Jun 19 | 0 | -17 | 11 | 6 |
| 31 Mar 19 | 0 | -16 | 9 | 6 |
| 31 Dec 18 | 0 | -16 | 9 | 6 |
| 30 Sep 18 | 0 | -15 | 8 | 7 |
| 30 Jun 18 | 0 | -19 | 12 | 7 |
| 31 Mar 18 | 0 | -18 | 11 | 7 |
| 31 Dec 17 | 0 | -19 | 12 | 7 |
| 30 Sep 17 | 0 | -19 | 11 | 7 |
| 30 Jun 17 | 0 | -14 | 7 | 7 |
| 31 Mar 17 | 0 | -13 | 7 | 6 |
| 31 Dec 16 | 0 | -11 | 5 | 6 |
| 30 Sep 16 | 0 | -12 | 6 | 6 |
| 30 Jun 16 | 0 | -11 | 6 | 5 |
| 31 Mar 16 | 0 | -10 | 5 | 5 |
| 31 Dec 15 | 0 | -9 | 4 | 5 |
| 30 Sep 15 | 0 | -7 | 2 | 4 |
Kaliteli Kazançlar: IMDX şu anda kârlı değil.
Büyüyen Kar Marjı: IMDX şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IMDX kârlı değildir ve zararlar son 5 yılda yılda 16.6% oranında artmıştır.
Büyüme Hızlandırma: IMDX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: IMDX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 43% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: IMDX 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/20 04:58 |
| Gün Sonu Hisse Fiyatı | 2026/05/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Insight Molecular Diagnostics Inc. 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| null null | KeyBanc Capital Markets Inc. |